AstraZeneca Plc and Bristol Myers Squibb recently engaged in preliminary discussions regarding a potential merger, which, if finalized, would establish a pharmaceutical giant valued at nearly $400 billion. The talks were first reported by the Financial Times and confirmed by sources familiar with the situation. While it's unclear if discussions are ongoing, a deal of this magnitude would be one of the largest in the pharmaceutical sector in recent years.
The proposed combination would merge AstraZeneca's $264 billion market capitalization with Bristol Myers Squibb's $133 billion valuation. Both companies have strong growth in cancer drugs; AstraZeneca's oncology treatments accounted for approximately $25 billion in 2025 sales, nearly half its total, while Bristol Myers' oncology drugs made up over 40% of its sales in the first half of 2026. This significant overlap in cancer immunotherapies is expected to draw considerable scrutiny from U.S. antitrust authorities, particularly under the Trump administration, which has focused on domestic investments and potential anti-competitive practices in the pharmaceutical industry.
Antitrust experts, like Andre Barlow of DBM Law Group, anticipate that the U.S. Federal Trade Commission (FTC) would thoroughly examine the merger, especially given the direct competition in certain drugs and late-stage pipeline assets. Meaningful divestitures, similar to the $13.4 billion sale of psoriasis treatment Otezla required during Bristol Myers' 2019 acquisition of Celgene, would likely be mandated. Beyond direct overlaps, the FTC is expected to consider broader issues such as product bundling and potential impacts on future innovation.
Bristol Myers Squibb is facing pressure from upcoming patent expirations on key medications, including cancer immunotherapy Opdivo and blood thinner Eliquis, which could lose patent protection by 2028. The company has been pursuing smaller deals to replenish its drug pipeline. AstraZeneca, on the other hand, has seen its share price quadruple under CEO Pascal Soriot's 14-year tenure, driven by strong demand for its cancer and rare-disease drugs. A potential deal would also follow AstraZeneca's successful defense against a takeover attempt by Pfizer in 2014.
Despite AstraZeneca's plans for a direct U.S. listing last year to capitalize on higher valuations, a merger with Bristol Myers Squibb would effectively involve a UK-based company acquiring a major U.S. pharmaceutical firm, a dynamic that could further complicate regulatory approval. Large pharmaceutical deals have been infrequent in recent years due to antitrust concerns and pressure to control drug prices, with notable exceptions including the Bristol Myers-Celgene deal, AbbVie's acquisition of Allergan in 2020, and the Takeda-Shire combination in 2019.
